FREQUENCY AND ROLE OF APO-E PHENOTYPE IN FAMILIAL HYPERCHOLESTEROLEMIA AND NONFAMILIAL HYPERLIPIDEMIA IN THE JAPANESE

被引:11
|
作者
KITAHARA, M
SHINOMIYA, M
SHIRAI, K
SAITO, Y
YOSHIDA, S
机构
[1] Second Department of Internal Medicine, School of Medicine, Chiba University, Chiba
关键词
Apo E phenotype; Apolipoprotein; Familial hypercholesterolemia; IDL; Lipoprotein metabolism; VLDL;
D O I
10.1016/0021-9150(90)90041-G
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The frequencies of the major apolipoprotein E(apo E) phenotypes in 65 normal, 426 hyperlipidemics, and 92 familial hypercholesterolemic Japanese subjects (FH) were studied, and features of hyperlipidemia compared between non-FH hyperlipidemia and FH. The frequencies of apo E phenotypes 3/3, 4/3, 3/2, 4/4 were almost the same in normal, non-FH hyperlipidemic, and FH subjects. The incidence of apo E7 was about 0.50 of total subjects. In type IV and V hyperlipidemias, incidence of E4/3 was higher than in any other hyperlipidemia. Incidence of E3/2 was also high in types III and V. In type II non-FH hyperlipidemia, incidence of E3/2 in type IIb was higher than in type Ila. VLDL-triglyceride, VLDL-cholesterol, apo C-II, apo C-III, and apo E levels were higher in E3/2 than in E3/3. But, in type IIa FH and type IIb FH, the incidence of E3/2 was the same, and lipid and apolipoprotein levels between 3/2 and 3/3 in FH were the same. These results indicate that allele ε{lunate}2 may be involved in the retention of VLDL or IDL, but not in FH. © 1990.
引用
收藏
页码:197 / 204
页数:8
相关论文
共 50 条
  • [41] APO-E ALLELE FREQUENCY IN PRIMARY ENDOGENOUS HYPERTRIGLYCERIDEMIA (TYPE-IV) WITH AND WITHOUT HYPERAPOBETALIPOPROTEINEMIA
    LUSSIERCACAN, S
    BOUTHILLIER, D
    DAVIGNON, J
    ARTERIOSCLEROSIS, 1985, 5 (06): : 639 - 643
  • [42] Low frequency of germline E-cadherin mutations in familial and nonfamilial gastric cancer
    Stone, J
    Bevan, S
    Cunningham, D
    Hill, A
    Rahman, N
    Peto, J
    Marossy, A
    Houlston, RS
    BRITISH JOURNAL OF CANCER, 1999, 79 (11-12) : 1935 - 1937
  • [43] GENETIC-POLYMORPHISM OF APOLIPOPROTEIN E AND HYPERLIPIDEMIA IN JAPANESE - FREQUENCIES OF APO-E5 AND APO-E7 IN MYOCARDIAL-INFARCTION SURVIVORS
    YAMANOUCHI, Y
    TSUCHIYA, S
    FIJIWARA, H
    MIYAZAKI, R
    HAMAGUCHI, H
    JAPANESE JOURNAL OF HUMAN GENETICS, 1987, 32 (02): : 136 - 136
  • [44] APOLIPOPROTEIN-E PHENOTYPE AND LIPOPROTEIN(A) IN FAMILIAL HYPERCHOLESTEROLEMIA - IMPLICATION FOR LIPOPROTEIN(A) METABOLISM
    LINDAHL, G
    MAILLY, F
    HUMPHRIES, S
    SEED, M
    CLINICAL INVESTIGATOR, 1994, 72 (08): : 631 - 638
  • [45] Early growth restriction programs an accelerated pro-atherosclerotic phenotype in Apo-E homozygous knockout mice
    Blackmore, H. L.
    Piekarz, A. V.
    Fernandez-Twinn, D. S.
    Mercer, J.
    Figg, N.
    Bennett, M.
    Ozanne, S. E.
    ATHEROSCLEROSIS, 2010, 213 (01) : E11 - E11
  • [46] The role of the insulin response element, located in the promoter region of the apo CIII gene, in familial combined hyperlipidemia
    Groenendijk, M
    Blom, NHHC
    deBruin, TWA
    DallingaThie, GM
    ATHEROSCLEROSIS, 1997, 134 (1-2) : 68 - 68
  • [47] The apo CIII gene locus in familial combined hyperlipidemia. The role of the insulin response element.
    DallingaThie, GM
    Groenendijk, M
    Blom, NHHC
    deBruin, TWA
    ATHEROSCLEROSIS, 1997, 130 : 129 - 129
  • [48] ROLE OF APO-B, APO-E AND LDL RECEPTOR GENE POLYMORPHISMS IN METABOLISM OF CHOLESTEROL AND LDL IN A HEALTHY MALE-POPULATION
    GYLLING, HK
    KONTULA, KK
    MIETTINEN, TA
    CIRCULATION, 1994, 90 (04) : 504 - 504
  • [49] EFFECT OF APOLIPOPROTEIN-E POLYMORPHISM AND XBAL POLYMORPHISM OF APOLIPOPROTEIN-B ON RESPONSE TO LOVASTATIN TREATMENT IN FAMILIAL AND NONFAMILIAL HYPERCHOLESTEROLEMIA
    OJALA, JP
    HELVE, E
    EHNHOLM, C
    AALTOSETALA, K
    KONTULA, KK
    TIKKANEN, MJ
    JOURNAL OF INTERNAL MEDICINE, 1991, 230 (05) : 397 - 405
  • [50] THE INFLUENCE OF APOLIPOPROTEIN-E PHENOTYPE ON THE RESPONSE TO LOVASTATIN THERAPY IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
    OMALLEY, JP
    ILLINGWORTH, DR
    METABOLISM-CLINICAL AND EXPERIMENTAL, 1990, 39 (02): : 150 - 154